Newsline

National Security , Newsline

Four Potential COVID-19 Therapeutics Enter Phase 2/3 Testing in NIH ACTIV-2 Trial

Posted on Friday, February 12, 2021
|
by Outside Contributor
|
0 Comments
|
Print

covid-19Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part of ACTIV-2, an adaptive trial designed to test investigational agents in non-hospitalized adult volunteers experiencing mild to moderate COVID-19 symptoms. ACTIV-2 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, and is led by the NIAID-funded AIDS Clinical Trials Group (ACTG).

You can read more from the National Institute of Allergy and Infectious Diseases here.

Share this article:
Subscribe
Notify of
guest
0 Comments
Most Voted
Newest Oldest
Inline Feedbacks
View all comments
Thanksgiving autumn place setting with cutlery and arrangement of colorful fall leaves with american flag
President Donald J. Trump attends the North Atlantic Treaty Organization plenary session Wednesday, Dec. 4, 2019, with NATO Secretary General Jens Stoltenberg and the British Prime Minister Boris Johnson at the 70th anniversary of NATO in Watford, Hertfordshire outside London. (Official White House Photo by Shealah Craighead)
NEW YORK, NEW YORK - DECEMBER 12: Dr. Marty Makary speaks during a screening of the HBO documentary film 'Bleed Out' on December 12, 2018 in New York City.
Thankful, grateful and blessed inspirational words with maple leaf Thanksgiving decorations

Stay informed! Subscribe to our Daily Newsletter.

"*" indicates required fields

0
Would love your thoughts, please comment.x
()
x

Subscribe to AMAC Daily News and Games